Clinical Trials Logo

Stage IV HCC clinical trials

View clinical trials related to Stage IV HCC.

Filter by:
  • None
  • Page 1

NCT ID: NCT04547452 Recruiting - Immunotherapy Clinical Trials

Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC

Start date: July 1, 2020
Phase: Phase 2
Study type: Interventional

Hepatocellular carcinoma (HCC) is a common malignancy, and more than 70% of newly diagnosed HCC patients already have advanced disease. Sorafenib and lenvatinib are recommended as first-line options for advanced HCC. The PD-1 monoclonal antibody,such as nivolumab and pembrolizumab, have been approved to treat the patients with advanced HCC by the FDA. Combining radiotherapy with immune checkpoints showed promising response rates and improved survival in several solid tumor types. The purpose of this randomized study is to determine whether stereotactic body radiation therapy (SBRT) combined with sintilimab (an anti-PD-1 antibody) will improve the response to the anticancer treatment compared to sintilimab alone in patients with advanced HCC. About 84 participants will be enrolled in this study. All will take part at West China Hospital, Sichuan University.